Phaseline

Companies › Alcon Research

Alcon Research: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Ophthalmology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Apraclonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 3Ocular HyperemiaJan 2027
AR-14034 SR implant
Unclear - presumed long-acting intravitreal implant
–Phase 1Neovascular Age-related Macular Degeneration (nAMD)Apr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07578363ApraclonidinePhase 3Ocular HyperemiaOphthalmologyJan 2027
NCT07531043ApraclonidinePhase 3Ocular HyperemiaOphthalmologyFeb 2027
NCT05769153AR-14034 SR implantPhase 1Neovascular Age-related Macular Degeneration (nAMD)OphthalmologyApr 2027

Targets

ADRA2A (1) ADRA2C (1) ADRA2B (1)

Companies with the same targets

Guangzhou Novaken Pharm BioXcel Therapeutics Teikoku Pharma USA Tarian Pharma Acer Therapeutics Santen SAS Pharmazz ARS Pharmaceuticals Terran Biosciences Australia Tecnoquimicas

Companies built like this

Santen SAS PolyActiva Taejoon Pharmaceutical Bausch & Lomb Huons

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.